Provided herein are novel compounds as S1P5 modulators, pharmaceutical compositions,
use of such compounds in treating neurodegenerative diseases, particularly Alzheimer's …

Introduction Siponimod, a potent and selective sphingosine-1-phosphate (S1P1, 5) agonist,
is the only therapeutic agent that has shown efficacy against disability progression, decline …

Siponimod (brand name Mayzent) is a sphingosine-1-phosphate (S1P) receptor modulator
used in the treatment and management of relapsing forms of multiple sclerosis (MS) in …

Objective: This study aimed to evaluate the adverse effects of the only approved drug for
SPMS treatment in the Split Dalmatian municipality. This was achieved by assessing …

Background: Multiple sclerosis (MS) is a disease that commonly occurs among individuals of
working age. Its symptoms are heterogeneous and affect people with MS (PwMS) …

Stroke is the leading cause for death and disability worldwide, and the search for novel drug
treatments has been affected by repeated clinical trial failures. One novel drug that has …

Обстежено 105 хворих на рецидивуюче-ремітуючий розсіяний склероз у віці від 18 до
49 років. Ступінь інвалідизації оцінювали за шкалою Expanded Disability Status Scale …

抄録 While immune modulation therapies have seen recent tremendous success in relapse
remitting multiple sclerosis (MS), our limited knowledge of pathogenesis hampers the …